FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092179907> ?p ?o ?g. }

• W2092179907 endingPage "548" @default.
• W2092179907 startingPage "541" @default.
• W2092179907 abstract "Background. Cost and clinically significant adverse effects are the major limiting factors of interferon (IFN) use in therapy for chronic hepatitis B virus (HBV) infection. A clinical trial was conducted in China to study the efficiency and clinical relevance of low-dose regimen of IFN treatment for chronic HBV infection and to reveal factors predicting sustained combined response. Methods. During a randomized, open-label control study, hepatitis B e antigen (HBeAg)–positive patients with chronic HBV infection (n = 230) were assigned to receive pegylated IFN-α-2b (1.0 µg/kg) (n = 115) or IFN-α-2b (3 MIU; n = 115) for a 24-week period. Sustained combined response was assessed 24 weeks after the completion of treatment. Results. The greater rate of HBeAg loss in the pegylated IFN-group (23%) was the only statistically significant difference between the 2 treatment arms observed at the end of follow-up. The results of the multivariate statistical analysis revealed that HBV genotype B and patient age (≤25 years) were 2 independent factors associated with sustained combined response. A total of 40% of patients with HBV genotype B aged ≤25-years achieved sustained combined response. Only 4 (1.7%) of 230 patients discontinued therapy because of clinically significant adverse effects. Conclusions. The choice of low-dose IFN regimen might be a relevant clinical option to reduce the cost and adverse effects of therapy for younger patients with chronic HBV infection and genotype B infection in countries where it is prevalent." @default.
• W2092179907 created "2016-06-24" @default.
• W2092179907 creator A5009887722 @default.
• W2092179907 creator A5010877809 @default.
• W2092179907 creator A5011767765 @default.
• W2092179907 creator A5016110407 @default.
• W2092179907 creator A5017053622 @default.
• W2092179907 creator A5019237114 @default.
• W2092179907 creator A5029936292 @default.
• W2092179907 creator A5031125583 @default.
• W2092179907 creator A5042519419 @default.
• W2092179907 creator A5056241757 @default.
• W2092179907 creator A5063481487 @default.
• W2092179907 date "2007-02-15" @default.
• W2092179907 modified "2023-10-08" @default.
• W2092179907 title "Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated Interferon- -2b for Hepatitis B e Antigen--Positive Patients with Chronic Hepatitis B in China" @default.
• W2092179907 cites W1965473659 @default.
• W2092179907 cites W1969629866 @default.
• W2092179907 cites W1996317692 @default.
• W2092179907 cites W2012090731 @default.
• W2092179907 cites W2037166866 @default.
• W2092179907 cites W2040740844 @default.
• W2092179907 cites W2048418494 @default.
• W2092179907 cites W2049902316 @default.
• W2092179907 cites W2054061813 @default.
• W2092179907 cites W2057591582 @default.
• W2092179907 cites W2062368700 @default.
• W2092179907 cites W2071291950 @default.
• W2092179907 cites W2074676714 @default.
• W2092179907 cites W2085800828 @default.
• W2092179907 cites W2101032357 @default.
• W2092179907 cites W2120128540 @default.
• W2092179907 cites W2123873622 @default.
• W2092179907 cites W2144375124 @default.
• W2092179907 doi "https://doi.org/10.1086/511042" @default.
• W2092179907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17243057" @default.
• W2092179907 hasPublicationYear "2007" @default.
• W2092179907 type Work @default.
• W2092179907 sameAs 2092179907 @default.
• W2092179907 citedByCount "73" @default.
• W2092179907 countsByYear W20921799072012 @default.
• W2092179907 countsByYear W20921799072013 @default.
• W2092179907 countsByYear W20921799072014 @default.
• W2092179907 countsByYear W20921799072015 @default.
• W2092179907 countsByYear W20921799072016 @default.
• W2092179907 countsByYear W20921799072017 @default.
• W2092179907 countsByYear W20921799072018 @default.
• W2092179907 countsByYear W20921799072019 @default.
• W2092179907 countsByYear W20921799072022 @default.
• W2092179907 countsByYear W20921799072023 @default.
• W2092179907 crossrefType "journal-article" @default.
• W2092179907 hasAuthorship W2092179907A5009887722 @default.
• W2092179907 hasAuthorship W2092179907A5010877809 @default.
• W2092179907 hasAuthorship W2092179907A5011767765 @default.
• W2092179907 hasAuthorship W2092179907A5016110407 @default.
• W2092179907 hasAuthorship W2092179907A5017053622 @default.
• W2092179907 hasAuthorship W2092179907A5019237114 @default.
• W2092179907 hasAuthorship W2092179907A5029936292 @default.
• W2092179907 hasAuthorship W2092179907A5031125583 @default.
• W2092179907 hasAuthorship W2092179907A5042519419 @default.
• W2092179907 hasAuthorship W2092179907A5056241757 @default.
• W2092179907 hasAuthorship W2092179907A5063481487 @default.
• W2092179907 hasBestOaLocation W20921799071 @default.
• W2092179907 hasConcept C126322002 @default.
• W2092179907 hasConcept C168563851 @default.
• W2092179907 hasConcept C197934379 @default.
• W2092179907 hasConcept C203014093 @default.
• W2092179907 hasConcept C2522874641 @default.
• W2092179907 hasConcept C2775940106 @default.
• W2092179907 hasConcept C2776178377 @default.
• W2092179907 hasConcept C2776461080 @default.
• W2092179907 hasConcept C2777382497 @default.
• W2092179907 hasConcept C2777410769 @default.
• W2092179907 hasConcept C2780040827 @default.
• W2092179907 hasConcept C2780593183 @default.
• W2092179907 hasConcept C2781413609 @default.
• W2092179907 hasConcept C2909179924 @default.
• W2092179907 hasConcept C3020491458 @default.
• W2092179907 hasConcept C71924100 @default.
• W2092179907 hasConcept C90924648 @default.
• W2092179907 hasConceptScore W2092179907C126322002 @default.
• W2092179907 hasConceptScore W2092179907C168563851 @default.
• W2092179907 hasConceptScore W2092179907C197934379 @default.
• W2092179907 hasConceptScore W2092179907C203014093 @default.
• W2092179907 hasConceptScore W2092179907C2522874641 @default.
• W2092179907 hasConceptScore W2092179907C2775940106 @default.
• W2092179907 hasConceptScore W2092179907C2776178377 @default.
• W2092179907 hasConceptScore W2092179907C2776461080 @default.
• W2092179907 hasConceptScore W2092179907C2777382497 @default.
• W2092179907 hasConceptScore W2092179907C2777410769 @default.
• W2092179907 hasConceptScore W2092179907C2780040827 @default.
• W2092179907 hasConceptScore W2092179907C2780593183 @default.
• W2092179907 hasConceptScore W2092179907C2781413609 @default.
• W2092179907 hasConceptScore W2092179907C2909179924 @default.
• W2092179907 hasConceptScore W2092179907C3020491458 @default.
• W2092179907 hasConceptScore W2092179907C71924100 @default.
• W2092179907 hasConceptScore W2092179907C90924648 @default.
• W2092179907 hasIssue "4" @default.

• next